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A Structured Exercise Program for Patients with Advanced
Non-small Cell Lung Cancer
Jennifer S. Temel, MD, Joseph A. Greer, PhD, Sarah Goldberg, MD, Paula Downes Vogel, PT, MS,
Michael Sullivan, PT MBA, William F. Pirl, MD, Thomas J. Lynch, MD, David C. Christiani, MD,
and Matthew R. Smith, MD, PhD
Introduction: Exercise improves functional outcome and symptoms
for certain cancer populations, but the feasibility, efficacy, and safety of
structured exercise in patients with lung cancer is unknown. In this
study, we examined the feasibility of a hospital-based exercise program
for patients with advanced non-small cell lung cancer.
Methods: This study included patients with newly diagnosed ad-
vanced stage non-small cell lung cancer and Eastern Cooperative
Oncology Group performance status 0–1. A physical therapist
facilitated twice-weekly sessions of aerobic exercise and weight
training over an 8-week period. The primary end point was feasi-
bility of the intervention, defined as adherence to the exercise
program. Secondary endpoints included functional capacity, mea-
sured by the 6-minute walk test and muscle strength, as well as
quality of life, lung cancer symptoms and fatigue, measured by the
Functional Assessment of Cancer Therapy-lung and Functional
Assessment of Cancer Therapy-fatigue scales.
Results: Between October 2004 and August 2007, 25 patients enrolled
in the study. All participants received anticancer therapy during the
study period. Twenty patients (80%) underwent the baseline physical
therapy evaluation. Eleven patients (44%) completed all 16 sessions.
An additional 6 patients attended at least 6 sessions (range, 6–15), and
2 patients only attended one session. Study completers experienced a
significant reduction in lung cancer symptoms and no deterioration in
their 6-minute walk test or muscle strength.
Conclusions: Although the majority of participants attempted the
exercise program, less than half were able to complete the interven-
tion. Those who completed the program experienced an improve-
ment in their lung cancer symptoms. Community-based or briefer
exercise interventions may be more feasible in this population.
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Exercise plays an important role in both primary andsecondary prevention of cancer and may impact the health
and functioning of patients with a current cancer diagnosis.1–6
Some of the more debilitating symptoms patients with cancer
experience, including fatigue, cachexia, depression, and anx-
iety, may be ameliorated with exercise.7–10 Both healthy and
medically ill patients consistently report quality of life (QOL)
improvements with exercise.11–13 The benefits of exercise for
individuals with cancer have been described in a number of
patient populations.14–21 However, the majority of studies
have been performed in patients with breast cancer and in
patients undergoing stem cell transplantation.9,10,17,18,22–29 Al-
though these studies have been informative regarding the
potential benefits of exercise in patients receiving anticancer
therapy, the extent to which these benefits are achievable in
other cancer populations, such as those with advanced dis-
ease, remains unknown.
Patients with metastatic, incurable solid tumors tend to
report the greatest symptom burden compared with other
cancer patient populations.30–33 For example, the majority of
patients with metastatic lung cancer experience clinically
significant fatigue and cachexia.34–38 Similarly, the preva-
lence of psychologic distress, including depression and anx-
iety symptoms, is highest among patients with cancers that
have poorer prognoses, such as lung and pancreatic malig-
nancies.39 Unfortunately, the results of pharmacotherapy tri-
als for treating cancer-related fatigue and anorexia/cachexia
have been disappointing to date.40–45
Targeted nonpharmacological interventions, such as exer-
cise, may serve as useful alternatives for managing cancer-
related symptoms in patients with advanced malignancies. Other
types of behavioral interventions, such as cognitive behavioral
therapy, multidisciplinary symptom management, and other in-
tegrative/complementary therapies have been shown to be useful
for managing cancer-related symptoms.21,46–49 Exercise is an
appealing strategy based on its universal health benefits, poten-
tial for mitigating declines in functional status, and its availabil-
ity to all patients. However, the feasibility of an exercise pro-
gram for patients with metastatic solid tumors, many of whom
are older with comorbid disease, has yet to be established. The
few published studies of exercise interventions with mixed
cancer populations have generally included patients with both
early and late stage disease.50–52
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The goal of this study was to assess the feasibility of a
structured exercise program for patients with newly diagnosed
advanced non-small cell lung cancer (NSCLC). In light of the
advanced age and frequency of comorbid conditions in this
patient population, we designed a hospital-based, supervised
exercise program to allow close monitoring and observation.
PATIENTS AND METHODS
Patient Selection
Patients within 12 weeks of diagnosis of advanced
NSCLC (stage IIIB with pleural or pericardial effusions or
stage IV) confirmed by histology or cytology were eligible
for this study. Other eligibility requirements included the
ability to ambulate for 6 minutes, an Eastern Cooperative
Oncology Group performance status of 0–1, and the ability to
read and respond to questions in English. Patients were
excluded from the study if they had unstable cardiac disease
(including congestive heart failure, unstable ischemia, or
arrhythmia), baseline anemia (Hemoglobin 10 g/dl), or
untreated bone or brain metastases that prevented participa-
tion. Thoracic oncology clinicians referred eligible patients
receiving primary oncology care at Massachusetts General
Hospital to the study. The study was reviewed and approved
by the Harvard Cancer Center Institutional Review Board.
All subjects provided written informed consent.
Assessment of Functional Capacity and Muscle
Strength
At baseline, subjects underwent an evaluation with a
senior physical therapist who was also responsible for facil-
itating the structured exercise program. Vital signs were
monitored throughout the initial evaluation and any signifi-
cant changes in heart rate or blood pressure were reported to
the patient’s oncologist. Screening for abnormal cardiovas-
cular and pulmonary response to exercise was assessed using
a symptom limited, submaximal Modified Bruce treadmill
test. By definition, this test may progress to 85% of a
participant’s age predicted maximal heart rate (computed by
208  0.7  age).53 Results of the Modified Bruce tread-
mill test, including cardiac rhythm measurements, were sent
to the oncologist for review.
The baseline evaluation included assessments of exercise
response, functional exercise capacity, and muscle strength.
Functional exercise capacity was measured with the 6-minute
walk test (6MWT), which is a commonly used measurement of
functional/exercise capacity in patients with pulmonary morbid-
ity.54,55 The 6MWT is the distance in meters a patient can
quickly ambulate on a flat, hard surface in 6 minutes. Finally,
the strength of major muscle groups associated with perform-
ing activities of daily living, including both the upper extrem-
ity (shoulder flexion, elbow flexion, elbow extension) and
lower extremity (hip extension, hip abduction, knee exten-
sion), was measured by the maximal amount of weight that
each muscle group can move through the available range of
motion (1 repetition maximum 1RM).56 All initial visit data
were analyzed and interpreted to prescribe individualized
exercise rehabilitation programs.
Structured Exercise Program
The 16-session exercise program was initiated the week
following the baseline evaluation. Sessions occurred twice
weekly over the course of 2 months. However, participants were
allowed to make up sessions missed due to illness as long as the
entire exercise programwas completed within a 12-week period.
The structured exercise sessions took place in group for-
mat (8–10 patients), each lasting approximately 90 to 120
minutes. Vital signs were assessed before each session. During
a 10-minute warm-up period, participants performed range of
motion and stretching exercises for the trunk and extremities.
Participants then completed 30 minutes of aerobic exercise
including 15 minutes on the treadmill and 15 minutes on an
upright bicycle. The Modified Borg Scale57 was used to monitor
patient symptoms of dyspnea on exertion and perceived exer-
tion. The goal level of intensity for the aerobic exercise was for
participants to achieve a heart rate between 70 and 85% of their
maximum or an exertion and perceived exertion of 13 (“some-
what hard”) for those unable to achieve their target heart rate. A
cool down period of 2 to 5 minutes followed the 15 minutes on
both the treadmill and the bicycle.58
For the strength training component of the exercise
program, patients performed 3 sets of 10 repetitions of 6
different exercises (i.e., 3 upper extremity and 3 lower ex-
tremity movements), starting at 60% of the 1RM and increas-
ing to 80% of the 1RM over the course of 16 sessions. These
strength training exercises took approximately 30 to 40 min-
utes and were modified or discontinued as necessary for
participants unable to complete them. During the final exer-
cise session, both the 6MWT and the final weight lifted by the
patient’s dominant arm (for 3 sets of 10 repetitions) were
recorded for analysis.
Quality of Life (QOL) and Symptom
Assessments
The following self-report questionnaires were adminis-
tered at the baseline physical therapy (PT) evaluation and after
completing the final session of the exercise-training program.
To evaluate health-related QOL and cancer-related
symptoms, we used the Functional Assessment of Cancer
Therapy (FACT).59 Measuring multiple dimensions of QOL
during the past week, the FACT-General (FACT-G) is a
26-item questionnaire in which patients rate their physical,
functional, emotional, and social well-being on a five-point
Likert scale. The FACT-Lung (FACT-L) consists of the
FACT-G plus a Lung Cancer Subscale (LCS) that addresses
seven symptoms specific to lung cancer, including cough,
shortness or breath, and chest discomfort.60 The optional
question regarding satisfaction with sex life was eliminated to
allow for ease of scoring. Additionally, study participants
completed the 13-item fatigue scale from the FACIT-Fatigue
questionnaire.61 A higher score on the total FACT or any of
its components indicates better QOL. A score of 24 or less on
the LCS and 30 or less on the fatigue scale is considered
indicative of clinical symptoms.61–63
We also administered the Hospital Anxiety and Depres-
sion Scale (HADS), a 14-item self-report instrument designed
to assess mood and anxiety symptoms in medically ill pa-
Temel et al. Journal of Thoracic Oncology • Volume 4, Number 5, May 2009
Copyright © 2009 by the International Association for the Study of Lung Cancer596
tients.64 Used widely in studies of patients with cancer, the
HADS consists of two seven-item subscales assessing depres-
sion and anxiety symptoms during the past week. Each
subscale ranges from 0 to 21, with a score of 8 or greater
suggestive of a possible case of depression or anxiety.
Feasibility Criteria for Structured Exercise
Program
The primary goal of this pilot study was to assess the
feasibility of a structured exercise-training program for patients
with advanced NSCLC. Patients who attended all 16 training
sessions during a 12-week period were classified as meeting the
adherence requirement. In pulmonary rehabilitation programs
involving chronic obstructive pulmonary disease patients, re-
ported adherence rates vary between 74 and 83%.65–67 Consid-
ering the degree of comorbid disease and poor overall health
status of patients with lung cancer, we proposed an adherence
rate of 70% to be an acceptable goal. Our target accrual during
the 3-year study period was 30 patients.
Statistical Analysis
All analyses were conducted with SPSS 15.0. To de-
termine adherence with the exercise program, we evaluated
the level of participation of each participant. We then calcu-
lated the rate of adherent patients over the total number of
patients to estimate the adherence of the entire sample.
For the secondary outcomes, we prospectively evalu-
ated QOL (FACT-L), symptom burden (LCS; FACT-Fa-
tigue), mood (HADS), functional capacity (6MWT), and
muscle strength (RM) in the sample. Descriptive statistics
were initially calculated to estimate the frequencies, means,
and standard deviations of the study variables. To assess
change in the outcome variables before and after participation
in the exercise intervention, we conducted two-sided, paired
samples t-tests. However, given the small sample size and
potential violations of parametric test assumptions, we re-
peated the analyses and reported p-values using the Wilcoxon
Signed Ranks Test. As this was a pilot feasibility study, we
did not correct for multiple comparisons.
Survival time was calculated from the date of consent to
the date of death using the Kaplan Meier method. Patients who
were alive on the date of last follow-up were censored on that
date.
RESULTS
Between October 2004 and August 2007, 25 patients
were accrued to the study. The baseline characteristics of
consented patients are shown in Table 1. All participants
received one of the following anticancer therapies: radiation
alone (8%), radiation during or followed by chemotherapy
(20%), or chemotherapy alone (72%). Chemotherapy regi-
mens included either a platinum-based doublet (19 of 25, 76%),
usually with an experimental third agent or with bevacizumab
(12 of 19, 63%), or a single oral agent (4 of 25, 16%). The
median survival of the study cohort was 12.98 months.
Study Feasibility
Of the 25 patients who signed informed consent, 20
(80%) completed the baseline PT evaluation (Figure 1). The
remaining five patients who did not receive the initial eval-
uation withdrew from the study due to rapid physical decline
(n 2), feeling unwell (n 2), or concerns about the amount
of travel (n  1).
Subsequent to the baseline PT evaluation, one patient
never participated in the exercise program. Two additional
patients withdrew from the study after only a single session:
one for clinical deterioration on chemotherapy (sustained a
fall) and the other for unspecified reasons. Of those who
participated in the exercise program, 11 patients attended all
16 sessions, resulting in a completion rate of 44%. Six patients
attended at least 6 sessions (range, 6–15) before withdrawing
due to deterioration in their health status (Figure 1).
Quality of Life and Symptom Assessment
The results regarding QOL, cancer-related symptoms
and mood are shown in Table 2 for the study participants who
completed baseline and poststudy assessments (n  11).
There were no statistically significant changes in QOL, fatigue,
or mood symptoms in participants from baseline to post assess-
ment. However, lung cancer symptoms significantly improved
over the course of the study, as measured by the LCS.
Exercise Outcomes
Table 3 details the results for the 6MWT as well as upper
and lower extremity strength-training exercises. Among partic-
ipants who completed baseline and poststudy assessments, the
distance walked in 6 minutes increased over the study period,
though this difference was not statistically significant. The
maximum weight lifted also increased for all six muscle
group exercises, achieving statistical significance for elbow
extension. For the strength training component of the pro-
gram, the final weight lifted was recorded not only at baseline
and postintervention, but also at each session. Therefore, we
repeated the analyses carrying the last end point forward for
all patients who completed strength training as long as phys-
TABLE 1. Baseline Patient Characteristics
Variable Number (%)
Age, years
Median 68
Range 48–81
Race, white 25 (100%)
Sex, female 16 (64%)
Performance status
0 10 (40%)
1 15 (60%)
Cancer stage
IIIB with effusions 4 (16%)
IV 21 (84%)
Smoking status
Current/former smoker 22 (88%)
Never smoker 3 (12%)
Initial therapy
Chemotherapy 18 (72%)
Chemotherapy and radiation 5 (20%)
Radiation 2 (8%)
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ically able (n  16). These findings replicated those of the
study completers shown in Table 3.
DISCUSSION
This investigation is one of the first studies to examine
the feasibility and potential benefit of a structured outpatient
exercise program in a homogenous, well-defined cohort of
patients with advanced cancer. Our study sample consisted of
25 patients with newly diagnosed incurable NSCLC. Because
these patients experience considerable fatigue, dyspnea, and
cachexia, they represent an ideal population to investigate an
intervention that may alleviate symptom burden and enhance
physical functioning.33 Additionally, consistent with previous
investigations of individuals with advanced lung cancer, the
patients in our sample tended to be older and have a history
of tobacco use. Should structured exercise interventions
prove feasible despite poor health status and comorbidity in
patients, such programs could substantially impact symptom
control and QOL.
The findings demonstrate that the majority of the sam-
ple (76%) either completed the exercise program or partici-
pated as long as physically able, despite failing to achieve the
TABLE 2. Mean Pre-Post Scores for QOL and Mood
Variable (n  11) Base Mean (SD) Post Mean (SD) 95% CI of Difference
FACT-L total score 103.44 (14.19) 104.66 (14.51) 8.69 to 6.24
Personal well-being 22.30 (5.48) 21.44 (6.59) 4.13 to 5.86
Social well-being 23.00 (3.00) 22.09 (3.02) 0.06 to 1.88
Functional well-being 18.45 (6.46) 18.82 (5.40) 4.00 to 3.27
Emotional well-being 19.45 (3.30) 19.91 (4.35) 2.46 to 1.55
Lung cancer subscale 20.23 (4.70) 22.77 (3.01) 4.94 to 0.15a
Trial outcome index 60.89 (13.24) 62.48 (12.34) 9.32 to 6.14
FACT-fatigue scale 35.35 (12.64) 38.77 (11.42) 11.17 to 4.32
HADS
Anxiety symptoms 2.91 (3.02) 2.36 (2.20) 1.46 to 2.55
Depression symptoms 3.73 (4.29) 4.45 (3.98) 4.02 to 2.57
a p  0.05.
CI, confidence interval; FACT, Functional Assessment of Cancer Therapy; FACT-L, FACT-Lung; HADS, Hospital Anxiety
and Depression Scale.
TABLE 3. Mean Pre-Post Scores for Functional Capacity
and Muscle Strength
Variable
Base Mean
(SD)
Post Mean
(SD)
95% CI of
Difference
Functional capacity
(n  11)
6 minute walk test 410.55 (83.28) 435.73 (72.66) 57.25 to 6.89
Muscle strength
Shoulder flexion
(n  11)
5.50 (1.96) 6.09 (2.66) 1.60 to 0.42
Elbow flexion
(n  11)
11.23 (5.59) 12.36 (6.71) 3.00 to 0.73
Elbow extension
(n  11)
5.64 (2.77) 6.82 (3.76) 2.12 to 0.24a
Hip extension
(n  10)
8.15 (4.90) 9.05 (6.88) 3.48 to 1.68
Hip abduction
(n  10)
8.20 (1.81) 9.75 (5.64) 4.56 to 1.46
Knee extension
(n  9)
23.11 (11.56) 27.83 (19.43) 12.90 to 3.45
a p  0.05.
CI, confidence interval.
Completed baseline PT 
assessment (n=20)
Participated in exercise 
program (n=19)
Signed informed consent (n=25)
Never exercised (n=1)
Participated but unable to complete due to:
Hospitalization (n=3)
Clinical deterioration on chemotherapy (n=2)
Retinal detachment (n=1)
Neuropathy/wheelchair bound (n=1)
Unspecified reasons (n=1)
Completed exercise program 
(n=11)
Did not completed baseline 
PT assessment (n=5)
FIGURE 1. Patient flow.
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target adherence rate to establish feasibility. Many patients
were unable to attend all sessions due to progressive/inter-
vening medical complications, resulting in a final completion
rate of 44%. Notably, participants did not experience any
significant detriment to their QOL or exacerbation of fatigue
symptoms over the study period. Those who completed the
program did experience a significant improvement in their
lung cancer symptoms, which is encouraging and may war-
rant further investigation. However, the findings should be
interpreted cautiously given the single-arm nature of this
study, small sample size, and use of multiple comparisons for
outcome variables.
In contrast to our study of patients with newly diag-
nosed advanced NSCLC, previous investigators have gener-
ally explored the benefits of exercise by sampling patients
with different types of cancer at variable times during the
course of disease. For example, one study examined the effect
of exercise in a sample of patients with mixed incurable
cancers receiving palliative care.51,52 Similar to our findings,
46% of enrolled patients completed the 6-week program and
experienced improvements in the 6MWT and some QOL
measures. However, only 27% of patients (9 of 34) received
chemotherapy during the study period. In another study,
Adamsen et al. demonstrated the feasibility of a multidimen-
sional exercise program for patients undergoing chemother-
apy. Yet, their study sample also included participants with
diverse malignancies, many of whom received adjuvant ther-
apy or chemotherapy with curative intent.50,68 In the only
study to evaluate the feasibility of an exercise program
specifically for individuals with lung cancer, potential partic-
ipants were referred for a nutrition and rehabilitation program
at any point during the course of their illness.69 Of the 168
patients referred to the program, only 92 were prescribed
exercise, since many patients were excluded due to pain
(66%) or cardiovascular instability (17%), among other rea-
sons. Of the patients eligible for exercise, 38 (40%) refused
the intervention, and only 17 (19%) completed at least 6
sessions in a 2-month period. The paucity of data in patients
with advanced lung cancer underscores the need for further
research to identify effective methods for reducing symptom
burden in patients with such significant morbidity.
Cancer-related fatigue may in part be the result of
cachexia associated with disease progression and anticancer
therapy.70 Therefore, in this novel study of patients with
advanced lung cancer, we sought to examine the effect of
exercise on muscle strength and level of functioning. Al-
though one recent investigation showed that, among patients
with lung cancer receiving chemotherapy, functional capacity
significantly declined as measured by the 6MWT, no such
decrements in functioning were seen in our study completers,
despite undergoing concurrent anticancer therapy.71 Simi-
larly, patients who participated in the exercise program main-
tained or improved their muscle strength on average over the
course of the study. These results suggest that the physical
benefits of exercise seen in other cancer populations also
apply to lung cancer patients.
Our study has a number of important strengths. First,
we included a well-defined homogenous population of pa-
tients with a new diagnosis of advanced NSCLC. Second, due
to overlapping symptoms and comorbid disease in patients
with lung cancer and chronic obstructive pulmonary disease,
the study intervention consisted of a pulmonary rehabilitation
exercise program. Additionally, the structured program was
supervised, which, in contrast to home-based programs, en-
sured not only the safety of medically ill participants but also
the accuracy and reliability of adherence rates. Finally, our
intervention included both aerobic and strength training com-
ponents, optimizing the potential for maintaining and enhanc-
ing physical performance.7,15
Several limitations of the study also deserve mention.
Because this was a small, pilot investigation, we did not
collect data on the total number of patients seen in the clinic
who met eligibility criteria as well as those who were offered
but deferred study participation. Although these data are
lacking, the average age and overall survival of our partici-
pants are fairly consistent with previous estimates for patients
with metastatic lung cancer.72 Additionally, although the data
suggest a clinical benefit from exercise with improvement in
lung cancer symptoms and muscle strength, these findings
will need to be confirmed with a randomized study. Finally,
as a single institution study performed at a tertiary care
center, the findings may not generalize to patients with
advanced cancer seeking oncology care in the community.
Because the study took place in an academic medical center,
many patients were simultaneously enrolled in clinical trials
for anticancer therapy, which may have influenced patients’
willingness to participate in additional trials, including the
present study.
Accrual to the study was slow, and we failed to meet
our goal of 30 patients. We did not collect data on why
patients who were offered the study opted not to participate.
Certainly, the challenges of facing a new lung cancer diag-
nosis and the accompanying symptoms and psychologic dis-
tress may have impacted patients’ willingness and ability to
participate in an exercise study. Anecdotally, clinic physi-
cians and nurse practitioners also commented that patients
deferred study participation because of concerns about com-
muting to the hospital twice weekly. Therefore, offering the
exercise program within the community may have increased
enrollment. In addition, our exercise program was quite
intensive and rigorous, requiring twice weekly visits for up to
2 hours. Although we modeled our program after pulmonary
rehabilitation programs for patients with chronic obstructive
pulmonary disease, twice weekly visits during anticancer
therapy may not be feasible for most patients with advanced
cancer.66,73,74 Modifying the exercise program to be less
frequent, less intensive, or perhaps home-based may be more
acceptable and reasonable for patients with metastatic
NSCLC. Lastly, we chose to limit the study sample to those
with advanced disease given the degree of morbidity and
potential benefit from the intervention. However, as demon-
strated in populations with breast cancer, exercise programs
may also be useful for patients with earlier stages of lung
cancer, such as those receiving adjuvant chemotherapy.23
Findings from the present study suggest that a struc-
tured, supervised exercise program may improve symptom
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burden and functional capacity in patients with advanced
NSCLC. However, given the slow accrual and somewhat low
completion rates, a less intensive, more accessible program
may be more feasible. Although a supervised program is still
preferable for those with comorbid disease and poor health
status, a weekly, community-based program would likely be
more acceptable to patients. Future research in this area
would also benefit from a multi-institutional study, as many
obstacles limit the accrual of patients with advanced cancer to
supportive care trials. Despite these challenges, preliminary
findings from the present investigation provide encouraging
evidence supporting the feasibility and benefit of structured
exercise in patients with advanced NSCLC receiving antican-
cer therapy.
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